Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients

Inclusion Criteria: 1. Males and non-pregnant females and aged more than 18 years; 2. Willing and able to adhere to visit schedules and all study requirements; 3. Subjects read and signed the study-specific informed consent. Exclusion Criteria: 1. Subject or his/her family is employed by the participated hospital; 2. Subjects received 2010-2011 seasonal influenza vaccine within the previous 6 months; 3. History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication; 4. Personal or family history of Guillain-Barré Syndrome; 5. An acute febrile illness within 1 week prior to vaccination; 6. Current upper respiratory illness, including the common cold or nasal congestion within 72 hours; 7. Subjects with influenza-like illness as defined by the presence of fever (temperature ≥ 38°C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough; 8. Female subjects who are pregnant during the study. 9. Patients who receive hemodialysis therapy less than 3 months. 10. Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent; 11. Immunodeficiency, or under immunosuppressive treatment. 12. Receipt of any vaccine within 1 week prior to study vaccination or expected receipt between Visit 1 (study vaccination) and Visit 2 (final collection of blood samples); 13. Receipt of any blood products, including immunoglobulin in the prior 3 months; 14. Any severe illness needed to be hospitalization within three months. 15. Underlying condition in the investigators' opinion may interfere with evaluation of the vaccine.